GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » Liabilities-to-Assets

SinoMab BioScience (HKSE:03681) Liabilities-to-Assets : 0.74 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. SinoMab BioScience's Total Liabilities for the quarter that ended in Dec. 2024 was HK$598.10 Mil. SinoMab BioScience's Total Assets for the quarter that ended in Dec. 2024 was HK$804.06 Mil. Therefore, SinoMab BioScience's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.74.


SinoMab BioScience Liabilities-to-Assets Historical Data

The historical data trend for SinoMab BioScience's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience Liabilities-to-Assets Chart

SinoMab BioScience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Liabilities-to-Assets
Get a 7-Day Free Trial 0.13 0.35 0.50 0.65 0.74

SinoMab BioScience Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.55 0.65 0.67 0.74

Competitive Comparison of SinoMab BioScience's Liabilities-to-Assets

For the Biotechnology subindustry, SinoMab BioScience's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's Liabilities-to-Assets falls into.


;
;

SinoMab BioScience Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

SinoMab BioScience's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=598.098/804.064
=0.74

SinoMab BioScience's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as

Liabilities-to-Assets (Q: Dec. 2024 )=Total Liabilities/Total Assets
=598.098/804.064
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SinoMab BioScience  (HKSE:03681) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


SinoMab BioScience Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


SinoMab BioScience Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Executives
Liu Wenyi 2201 Interest of corporation controlled by you
Qiang Jing
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hainan Haiyao Co. Ltd. 2101 Beneficial owner
Leung Shui On 2201 Interest of corporation controlled by you
West Biolake Holdings Limited 2101 Beneficial owner
Skytech Technology Limited 2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch 2106 Person having a security interest in shares
Xu Sijia 2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She 2106 Person having a security interest in shares
Apricot Oversea Holdings Limited 2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si 2101 Beneficial owner
Hai Nan Hai Yao Gu Fen You Xian Gong Si 2101 Beneficial owner

SinoMab BioScience Headlines

No Headlines